Intraneuronal accumulation and persistence of radiolabel in rat brain following in vivo administration of [3H]-chlorisondamine
- PMID: 8581291
- PMCID: PMC1909043
- DOI: 10.1111/j.1476-5381.1995.tb15102.x
Intraneuronal accumulation and persistence of radiolabel in rat brain following in vivo administration of [3H]-chlorisondamine
Abstract
1. Chlorisondamine (CHL), a bisquaternary amine, produces a remarkably long-lasting blockade of central responses to nicotine. The mechanism underlying this blockade is not known. The main aim of this study was to test for possible accumulation of [3H]-CHL in rat brain during the period of chronic blockade. 2. Rats received CHL, either systemically (10 mg kg-1) or centrally (10 micrograms i.c.v.). Seven days later, striatal synaptosomes prepared from these animals were tested for nicotine-induced [3H]-dopamine release. This experiment showed that i.c.v. administration of CHL was as effective as systemic administration in producing ex vivo blockade of central nicotinic receptors. 3. Rats received bilateral i.c.v. infusions of [3H]-CHL (10 micrograms) and radioactivity was subsequently quantified in dissected cerebral cortex, striatum, hippocampus, midbrain and cerebellum. Radiolabel was detected at all three survival times (1, 7, and 21 days). Regional heterogeneity was apparent at 7 and 21 days survival. Radiolabel was almost exclusively confined to the insoluble subcellular fraction in all areas sampled. 4. The anatomical distribution of radiolabel was also visualized in brain sections. Rats received bilateral i.c.v. infusions of [3H]-CHL (10 micrograms) and were killed at 1, 7, 21 or 84 days. Immediately before they were killed, all rats were tested behaviourally, and central nicotinic blockade was demonstrated at 1, 7 and 21 days; partial recovery was observed at 84 days. Particularly at longer survival times, tritium was found to be heavily concentrated in the substantia nigra pars compacta, ventral tegmental area, dorsal raphé nucleus, and the granular layer of the cerebellum. 5. The possibility of retrograde axonal transport of radiolabel was then examined. Rats received a unilateral intrastriatal infusion of [3H]-CHL (0.34 or 0.034 micrograms) one week before they were killed. Autoradiographic labelling was largely confined to the site of infusion and to the ipsilateral substantia nigra pars compacta and dorsal raphé nucleus. 6. Thus, after i.c.v. administration, CHL (and/or centrally-formed derivatives) is initially widely distributed within the brain and is then selectively retained within a few brain areas. A persistent accumulation occurs within putative dopaminergic and 5-hydroxytryptaminergic neurones, at least partly through uptake by terminals and/or axons followed by retrograde transport. This persistent and anatomically-selective intraneuronal accumulation possibly underlies the long-term central nicotinic blockade associated with chlorisondamine.
Similar articles
-
Effects of nicotine and chlorisondamine on cerebral glucose utilization in immobilized and freely-moving rats.Br J Pharmacol. 2000 Jan;129(1):147-55. doi: 10.1038/sj.bjp.0703005. Br J Pharmacol. 2000. PMID: 10694214 Free PMC article.
-
Persistent nicotinic blockade by chlorisondamine of noradrenergic neurons in rat brain and cultured PC12 cells.Br J Pharmacol. 1998 Nov;125(6):1218-27. doi: 10.1038/sj.bjp.0702215. Br J Pharmacol. 1998. PMID: 9863650 Free PMC article.
-
Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered in vivo.Br J Pharmacol. 1994 Feb;111(2):414-8. doi: 10.1111/j.1476-5381.1994.tb14750.x. Br J Pharmacol. 1994. PMID: 8004385 Free PMC article.
-
Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.Br J Pharmacol. 1996 Feb;117(4):595-606. doi: 10.1111/j.1476-5381.1996.tb15232.x. Br J Pharmacol. 1996. PMID: 8646402 Free PMC article.
-
Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro.Br J Pharmacol. 1994 Feb;111(2):406-13. doi: 10.1111/j.1476-5381.1994.tb14749.x. Br J Pharmacol. 1994. PMID: 8004384 Free PMC article.
Cited by
-
Forebrain substrates of reward and motivation.J Comp Neurol. 2005 Dec 5;493(1):115-21. doi: 10.1002/cne.20689. J Comp Neurol. 2005. PMID: 16254990 Free PMC article. Review.
-
Effects of nicotine and chlorisondamine on cerebral glucose utilization in immobilized and freely-moving rats.Br J Pharmacol. 2000 Jan;129(1):147-55. doi: 10.1038/sj.bjp.0703005. Br J Pharmacol. 2000. PMID: 10694214 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous